Epilepsies that present during childhood pose unique challenges and include developmental and epileptic encephalopathies, specific distinctive constellations, and epilepsies with seizure subtypes, such as epileptic spasms, myoclonic-atonic seizures, and myoclonic absences. Self-limited focal epilepsies and genetic generalised epilepsy phenotypes are also evident during childhood. However, determining the cause-whether structural, genetic, metabolic, infectious, or autoimmune-is increasingly relevant. Although history and clinical examination form the fundamental basis of diagnosis, exclusion of epilepsy mimics in childhood can prove challenging, requiring specialist input and supportive electrophysiology. With crucial evidence-based medicine emerging on the treatment of infantile epileptic spasm syndrome, Dravet syndrome, and Lennox-Gastaut syndrome, with a focus on improving outcomes, early identification of surgically remediable epilepsies is crucial for neurodevelopmental outcomes. Practical questions remain regarding pathophysiology, the effects of causative factors and interictal epileptiform activity on cognition, and the efficacy of precision medicine-based approaches based on insights from epilepsy genetics.

Despite the availability of biological therapies, suboptimal disease control remains a problem for patients with Crohn's disease. We report the results of the GALAXI-2 and GALAXI-3 studies, which aimed to assess the efficacy and safety of intravenous induction followed by subcutaneous maintenance therapy with guselkumab over 48 weeks in adults with moderately to severely active Crohn's disease.

The primary analysis of this phase 3 trial combining talazoparib with enzalutamide demonstrated significantly improved radiographic progression-free survival (rPFS) versus enzalutamide plus placebo in patients with metastatic castration-resistant prostate cancer unselected for homologous recombination repair (HRR) gene alterations. Overall survival data were immature at that time. Here we report the final prespecified overall survival analysis, an updated descriptive analysis of rPFS, and safety in the cohort unselected for HRR gene alterations.